Correction to: Pharmacokinetics of Hormonal Contraception in Individuals with Obesity: a Review
- PDF / 119,046 Bytes
- 2 Pages / 595.276 x 790.866 pts Page_size
- 25 Downloads / 161 Views
CORRECTION
Correction to: Pharmacokinetics of Hormonal Contraception in Individuals with Obesity: a Review Shaalini Ramanadhan 1 & William J. Jusko 2 & Alison Edelman 1
# Springer Science+Business Media, LLC, part of Springer Nature 2020
Correction to: Curr Obstet Gynecol Rep (2020) 9:72–78. https://doi.org/10.1007/s13669-020-00284-y The original version of this article unfortunately contained some mistakes. In Table 2 and Table 3, complete and correct bibliographical information especially for the missing works of Foegh 2013 [31], Westhoff 2012 [32], Segall-Gutierrez 2010 [33], Sivin 1997 [34], Sivin 2001 [35], Mornar 2012 [36], Hidalgo 2009 [37] and Seeber 2012 [38] are hereby listed as part of the Reference List. 27. Doose DR, Wang SS, Padmanabhan M, Schwabe S, Jacobs D, Bialer M. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia. 2003;44(4):540–9. 28. Edelman AB, Carlson NE, Cherala G, Munar MY, Stouffer RL, Cameron JL, et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic–pituitary–ovarian activity. Contraception. 2009;80(2):119–27. 29. Westhoff CL, Torgal AH, Mayeda ER, Pike MC, Stanczyk FZ. Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. Contraception. 2010;81(6):474–80.
The online version of the original article can be found at https://doi.org/ 10.1007/s13669-020-00284-y * Shaalini Ramanadhan [email protected] 1
Oregon Health & Science University, Portland, OR 97239, USA
2
Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 14214, USA
30. Edelman AB, Cherala G, Munar MY, Dubois B, McInnis M, Stanczyk FZ, et al. Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users. Contraception. 2013;87(2):220–6. 31. Foegh M, Archer DF, Stanczyk FZ, Rubin A, Mishell DR. Ovarian activity in obese and nonobese women treated with three transdermal contraceptive patches delivering three different doses of ethinyl estradiol and levonorgestrel. Contraception. 2013;87(2):201–11. 32. Westhoff CL, Torgal AH, Mayeda ER, Petrie K, Thomas T, Dragoman M, et al. Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women. American Journal of Obstetrics and Gynecology. 2012;207(1):39.e1–.e6. 33. Segall-Gutierrez P, Taylor D, Liu X, Stanzcyk F, Azen S, Mishell DR. Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously. Contraception. 2010;81(6):487–95. 34. Sivin I, Lähteenmäki P, Ranta S, Darney P, Klaisle C, Wan L, et al. Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants. Contraception. 1997;55(2):81–5. 35. Sivin I, Wan L, Ranta S, Alvarez F, Brache V, Mishell DR, et al. Levonorgestrel concentrations during 7 years of continuous use of Jadelle contraceptive implants
Data Loading...
